⁃ Age \>= 18 years

⁃ Life expectancy of twelve weeks or more

⁃ Histologically or cytologically confirmed locally advanced or metastatic DTC that cannot be removed by surgery or radiotherapy, including papillary thyroid cancer, follicular thyroid cancer, hurthle cell thyroid cancer or poorly differentiated thyroid cancer.

⁃ At least one measurable lesion according to RECIST 1.1

⁃ Radioiodine-refractory (RAI-refractory) differentiated thyroid cancer can be diagnosed when any of the following criteria are met under thyroid-stimulating hormone (TSH) stimulation (\>30 mU/L) in the absence of exogenous iodine interference:

∙ Negative uptake in one or more measurable lesions after receiving I-131 treatment or scanning

‣ One or more measurable lesions that has progressed as per RECIST 1.1 within 14 months of 131I therapy（3.7\

• 4 GBq or100\

⁃ 200 mCi）,despite demonstration of radioiodine avidity at the time of that treatment by pre- or post-treatment scanning.

‣ Cumulative activity of 131I of \> 22 GBq or 600 mCi, with the last dose administered at least 6 months prior to study entry

⁃ Subjects with DTC who failed with or was intolerant to at least one prior tyrosine kinase inhibitor (TKI) therapy. If prior treatment with VEGFR-TKI, no more than two VEGFR-TKIs were allowed.

⁃ Recommendation of subject offering archived tissue sample or previous biomarker of MET test report. If archived tumor sample is not available, a fresh biopsy is optional, which need to be taken from needle biopsy or core needle biopsy (fine needle biopsy not allowed). Subjects who cannot provide tissue samples or test reports may still be eligible to participate if the investigator determines a potential clinical benefit from ST-1898 therapy.

⁃ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

⁃ TSH-suppression therapy is well tolerated with thyroid stimulating hormone (TSH) \< 0.5 mU/L;

‣ The patient has adequate organ and bone marrow function as follows:

• Adequate bone marrow function (without transfusion or colony stimulating factor support within 2 weeks): hemoglobin ≥ 90 g/L, absolute neutrophil count (ANC) ≥ 1.5 ×10\^9/L and platelets ≥ 100 × 10\^9/L;

∙ Adequate liver function: Bilirubin ≤ 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if participant has liver metastases);

∙ Adequate renal function: Serum creatinine ≤1.5 ×ULN or creatinine clearance≥50 mL/min per the Cockcroft-Gault formula;

∙ Adequate blood coagulation function: International Normalized Ratio (INR) ≤ 1.5 and Activated partial thromboplastin time (APTT) ≤1.5 ULN（except for the prophylactic use of anticoagulants）

∙ Adequate cardiac function: Left ventricular ejection fraction (LVEF) ≥50%;

∙ Participants having≤ 1 + proteinuria or ≥2+ proteinuria with urine protein \< 1 g/24 hour.

‣ Ability to understand and the willingness to sign a written informed consent document. The results of routine examination during the corresponding window period before screening are acceptable.

‣ Women with child-bearing potential and men must agree to use adequate contraception (e.g., hormonal contraceptives, male or female condom, or abstinence) during the course of the study and for at least 3 months following the last dose of study drug. Women with childbearing potential must have a negative serum pregnancy test within 7 days before first study treatment.